5443092025-04-012025-06-305443092025-04-012025-06-30in-capmkt:OtherExpenses1Member5443092025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15443092025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25443092025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss15443092025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss2iso4217:INRiso4217:INRxbrli:shares544309IKSNOTLISTEDINE115Q01022INVENTURUS KNOWLEDGE SOLUTIONS LIMITEDMain BoardEquity2025-04-012026-03-312025-07-312025-07-24INRMillionsQuarterlyFirst quarterSingle segmentCARE ENABLEMENT PLATFORM PROVIDING TECHNOLOGY ENABLED SOLUTIONS TO HEALTHCARE PROVIDERS2025-07-3119:30:002025-07-3120:45:00Not applicable2025-04-012025-06-30UnauditedConsolidated7400950000311300007432080000000395962000018079000027903000010638200005483260000194882000001948820000572200000-138770000433430000015153900000000151539000062280000157767000017026000019.078.85009.078.85Notes to the Statement of Unaudited Consolidated and Standalone Financial Results for the quarter ended June 30, 2025 <BR> <BR> 1. The above standalone financial results of Inventurus Knowledge Solutions Limited (the Company) and consolidated financial results of the Company and its subsidiaries (collectively the Group) for the quarter ended June 30, 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on July 31, 2025. The above results for the quarter ended June 30, 2025 have been reviewed by the Statutory Auditors of the Company in terms of Regulation 33 of the SEBl (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The figures for the quarter ended June 30, 2024 as reported in the statement have been approved by the Company's Board of Directors but have not been subjected to limited review since the requirement of submission of quarterly financial results is applicable on listing of equity shares of the Company from the quarter ended December 31, 2024. <BR> 2. The statement has been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder. <BR> <BR> 3. The figures of the quarter ended March 31, 2025 are balancing figures between the audited figures in respect of the full financial year ended on March 31, 2025 and the unaudited published year to date figures upto third quarter ended on December 31, 2024, which were subjected to Limited review by the Statutory Auditors. <BR> 4. The Group operates in one reportable business segment which comprises a Care enablement platform providing technology enabled solutions to Healthcare providers. This in the context of Indian Accounting Standard (Ind AS 108) Operating Segments, constitutes a single operating segment. <BR> 5. During the quarter ended June 30, 2025, the Company has allotted 23,942 shares (previous period, 464,800 shares) to eligible employees on exercise of Employee Stock options, in accordance with the terms and conditions of the IKS Employees Stock Options Plan 2022 named IKS Health - ESOP Policy 2022 as approved by the shareholders of the Company on April 22, 2022. Accordingly, the Company has transferred Rs. 3.51 million to the Securities Premium during the quarter ended June 30, 2025. Further, during the quarter ended June 30, 2025, the Company has granted 287,500 stock options respectively to eligible employees, as approved in the Nomination and Remuneration Committee meeting. The related share based compensation expense for the quarter ended June 30, 2025 is Rs.12.70 million. <BR> <BR> 6. The Board of Directors of the Company at its Meeting held on June 30, 2025, approved investment upto USD 17,000,000 by Inventurus Knowledge Solutions Inc, a subsidiary of the Company in IKS WWMG MSO LLC (Target Company) by subscribing upto 17,000,000 Common Units of the Target Company, which will result in acquisition of 48.02% of the outstanding equity interests of the Target Company by Inventurus Knowledge Solutions Inc. The contractual Purchase Closing Date is July 2, 2025 being the date on which Company has made the required payment as per the Purchase closing terms. <BR> 7. Earnings per share for the interim periods are not annualised. <BR> 8. The consolidated financial results of the Group include the results of its subsidiary companies viz: Inventurus Knowledge Solutions Inc, IKS Cares Foundation and its step down subsidiary companies viz: Aquity Holdings Inc, Aquity Solutions LLC, Aquity Solutions India Private Limited, Aquity Solutions Australia Pty Limited and Aquity Canada ULC.Other expenses1063820000Not Applicable, refere note 4. of the statement of unaudited financial results for the quarter ended June 30, 2025.Remeasurement of post employment benefit obligations-14250000Changes in the fair value of equity investments at FVOCI0-14250000-3750000Gains/ (losses) on cash flow hedges (net)68040000Exchange differences on translation of financial statements of foreign operations19580000876200001484000062280000